New Delhi, Oct 10: Alkem Laboratories Ltd on Thursday said it has entered into a licensing agreement with US-based Sonnet BioTherapeutics Holdings, Inc to develop, manufacture and commercialise a new drug candidate ‘SON-080’ for treatment of diabetic peripheral neuropathy in India. Under the licensing agreement, Alkem will carry out the clinical development of ‘SON-080’ in India with support from Sonnet and enable global and India regulatory filings, the company said in a regulatory filing. Alkem has exclusive rights to develop, […]

The post Alkem inks licensing pact with Sonnet BioTherapeutics for drug to treat diabetic neuropathy appeared first on Daily Excelsior.